<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">The Safe Stop trial also addresses the challenges physicians are facing during the current pandemic with coronavirus disease 2019 (COVID-19), including capacity issues in oncological care [
 <xref ref-type="bibr" rid="CR44">44</xref>]. The design of the Safe Stop trial obviously contributes to a reduction in hospital visits and costs during this pandemic. Although it is yet not known whether patients treated with ICIs have a higher risk of (a severe course of) COVID-19, the Safe Stop trial may limit the risk of ICI associated AEs and thereby the use of immunosuppressive drugs. In contrast to other clinical trials, it has not yet been necessary to put the Safe Stop Trial on-hold during the COVID-19 pandemic, which is the result of its accessible trial design and additional value during this ongoing pandemic.
</p>
